Haemonetics (HAE) Asset Writedowns and Impairment (2013 - 2026)

Haemonetics has reported Asset Writedowns and Impairment for 13 years, with the latest figure at $77.2 million in Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $77.2 million in Q1 2026; TTM through Mar 2026 was $95.1 million, a N/A change from a year earlier, with the FY2026 full-year figure at $86.5 million, up 3519.66% from the prior year.
• Asset Writedowns and Impairment was $77.2 million for Q1 2026 at Haemonetics, up from $9.3 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $77.2 million in Q1 2026, with the low at $94000.0 in Q3 2022.
• Average Asset Writedowns and Impairment over 4 years is $16.4 million, with a median of $5.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Asset Writedowns and Impairment plunged 98.17% in 2022, then sank 81.74% in 2023.
• Over 4 years, Asset Writedowns and Impairment stood at $94000.0 in 2022, then surged by 445.74% to $513000.0 in 2023, then soared by 1712.87% to $9.3 million in 2025, then jumped by 730.6% to $77.2 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at $77.2 million (Q1 2026), $9.3 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.